【摘要】 PPARγ配体在抗肿瘤中发挥着重要的作用,这些配体具有抗肿瘤、诱导分化和抗血管生成等效果.目的主要是评估PPARγ激动剂罗格列酮对结肠癌细胞株HT-29生长的抑制作用.结果显示,罗格列酮可以有效地抑制体外培养的结肠癌细胞株HT-29的生长及克隆形成,并能抑制HT-29裸鼠移植瘤的生长.与此同时,罗格列酮能够升高PPAR,γp-PPARγ的表达水平.以上结果初步证明罗格列酮在体内外均可抑制结肠癌细胞株HT-29的成长,提示罗格列酮有可能发展成为治疗结肠癌的有效药物.更多还原

【Abstract】 Peroxisome proliferators-activated receptors(PPARs) ligands play an important role in antitumorigenesis due to their anti-proliferative,pro-differential and anti-angiogenic effects.The aim of this study is to evaluate the effect of PPARγ ligand rosiglitazone(ROZ) on the growth and proliferation in human colorectal cancer cell line HT-29.The effect of ROZ on HT-29 cell proliferation were measured by MTT and colony formation assay.DNA and protein synthesis were examined by -Thymidine and -Leucine incorporation assay respectively.PPARγ expression was detected by RT-PCR and Western blotting analysis.ROZ inhibited cell proliferation,colony formation and inhibited the tumor growth of HT-29 in immunodeficient mice.Simultaneously,it increased the expression of PPARγ,p-PPARγ.These results indicated that ROZ inhibited growth of HT-29 cells in vitro and in vivo.It suggested that ROZ might be a promising therapeutic agent for colon cancer.更多还原